According to Ultragenyx's latest financial reports the company's total liabilities are $1.21 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $1.21 B | 1.9% |
2022-12-31 | $1.19 B | 98.88% |
2021-12-31 | $0.59 B | -0.88% |
2020-12-31 | $0.60 B | 25.63% |
2019-12-31 | $0.48 B | 335.37% |
2018-12-31 | $0.11 B | 3.12% |
2017-12-31 | $0.10 B | 60.98% |
2016-12-31 | $66.65 M | 134.04% |
2015-12-31 | $28.47 M | 118.7% |
2014-12-31 | $13.02 M | 36.5% |
2013-12-31 | $9.54 M | 139.94% |
2012-12-31 | $3.97 M | 167.56% |
2011-12-31 | $1.48 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Lexicon Pharmaceuticals
LXRX | $0.13 B | -88.73% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | $0.66 B | -45.64% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | $0.61 B | -49.19% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $1.89 B | 55.48% | ๐บ๐ธ USA |